Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CTSC | P53634 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039345 | 0.89 | MAPT (0.47) | LMNAHTTMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1039346 | 0.86 | PIK3CA (0.46) | LMNAHTTMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1036556 | 0.84 | LMNA (0.49) | LMNAHTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1040988 | 0.83 | MAPT (0.56) | LMNAHTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1036710 | 0.83 | POLB (0.53) | LMNAPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1039223 | 0.82 | MAPT (0.54) | LMNAHTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1037744 | 0.82 | MAPT (0.50) | LMNAHTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1041142 | 0.82 | CCR2 (0.48) | LMNAHTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1038627 | 0.80 | ALK (0.47) | LMNAHTTMAPTNPSR1MEN1 | |
| SCHEMBL16335068 | 0.76 | CYP3A4 (0.47) | LMNAHTTMAPTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349862-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL HEALTHCARE LIMITED (IN) | 2013-01-08 | — | — | US | claimed |
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | claimed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | claimed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | claimed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | claimed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | claimed |
| US-8349862-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL HEALTHCARE LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | disclosed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | disclosed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | disclosed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | disclosed |
| EP-2094663-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035305-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | LMNA 3509/4885HTT 3079/4885MAPT 3034/4885 |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | LMNA 3509/4885HTT 3079/4885MAPT 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.